Skip to main content
. Author manuscript; available in PMC: 2020 Jun 10.
Published in final edited form as: JAMA Oncol. 2015 Oct;1(7):907–915. doi: 10.1001/jamaoncol.2015.2524

Table 3.

Characteristics of Participants With Human Papillomavirus Type 16 (HPV16) DNA Detected in Any Posttreatment Oral Rinse

ID HPV16 DNA
Detection in
Oral Rinses
Smoking
Status
T
Stage
N
Stage
Primary
Treatment
Clinical
Follow-up
After
Diagnosis, mo
Site of
Recurrence
Salvage
Treatment
Time From First
HPV16-Positive
Posttreatment
Oral Rinse to
Recurrence, mo
Vital Status
at Last
Follow-up
1 Persistent Never T2 N2b CRT 24.2 Local, regional, distant CT 10.9 AWD
2 Persistent Former T4 N2c CRT 20.0 Regional, distant CT NAa DOD
3 Persistent Never T2 N2c CRT 36.8 Local Surgery + RT 6.9 NED
4 Persistent Never T3 N2c CRT 34.6 Local, regional Surgery, then CT, then palliative RT 3.7 DOD
5 Persistent Current T2 N2b Surgery + RT 36.2 Distant CT 7.0 DOD
6 New after treatment Never T3 N2c CRT 23.0 NAb NAb NAb NED

Abbreviations: AWD, alive with disease; CT, chemotherapy; CRT, chemoradiotherapy; DOD, died of disease; NA, not applicable; NED, no evidence of disease; RT, radiation therapy.

a

First posttreatment oral rinse obtained after diagnosis of recurrence.

b

Patient 6 did not have disease recurrence during the study period.